Today: 7 February 2026
Subscribe
Browse Category

NYSE:MRK News 14 November 2025 - 20 December 2025

Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen

Merck & Co., Inc. (NYSE: MRK) finished Friday’s regular session (Dec. 19, 2025) modestly higher, then eased slightly in after-hours trading as investors digested a headline-heavy day featuring U.S. drug-pricing policy moves and FDA acceleration for two major Merck pipeline assets. Below is what happened after the bell, why it matters, and the key items to track before the next U.S. market open (Monday, Dec. 22, 2025). MRK stock price after the bell: the key numbers Merck shares closed at $101.09, up $0.40 (+0.40%) on Friday. Zacks+1 In after-hours trading, MRK was slightly lower, trading around $100.9–$101.0 in early evening
20 December 2025
··
Merck (MRK) Stock After Hours: Key News, Analyst Calls, and What to Watch Before the Dec. 19, 2025 Market Open

Merck (MRK) Stock After Hours: Key News, Analyst Calls, and What to Watch Before the Dec. 19, 2025 Market Open

Merck & Co., Inc. (NYSE: MRK) ended Thursday, December 18, 2025, on a strong note—and then barely budged after the closing bell—after a day that mixed a bullish analyst upgrade with a fresh round of healthcare-policy headlines and pipeline developments that investors are still digesting. MRK closed up 1.52% at $100.69 and was fractionally higher in after-hours trading at last check. MarketWatch+1 Below is a complete, investor-focused rundown of what happened after the bell, what drove today’s coverage, and what matters most before Friday’s U.S. market open (Dec. 19, 2025). MRK after-hours check: where Merck stock stands tonight Merck stock
19 December 2025
·
Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

December 18, 2025 — Merck & Company, Inc. (NYSE: MRK) is back in the spotlight for investors today as three threads converge: a fresh Wall Street upgrade tied to Merck’s post‑Keytruda strategy, a potentially meaningful FDA fast‑track development for two pipeline assets, and new Phase 3 momentum for the company’s blockbuster oncology franchise in earlier‑stage bladder cancer. Merck shares traded around $101 intraday on Thursday, reflecting a modest gain versus the prior close, as markets absorbed a busy stream of pharma catalysts and analyst commentary. StockAnalysis Below is a comprehensive, publication‑ready roundup of the key news, forecasts, and analyses dated
18 December 2025
··
Merck (MRK) Stock After Hours: FDA Fast‑Track Vouchers, Keytruda‑Padcev Trial Win, and What to Watch Before the Dec. 18 Market Open

Merck (MRK) Stock After Hours: FDA Fast‑Track Vouchers, Keytruda‑Padcev Trial Win, and What to Watch Before the Dec. 18 Market Open

Merck & Co., Inc. (NYSE: MRK) finished regular trading on Wednesday, Dec. 17, 2025 in positive territory, then held near the $99 level in extended hours as investors weighed two major pipeline headlines—one before the opening bell and another after the close—alongside a renewed policy backdrop around U.S. drug pricing. Investing.com+1 Below is what moved MRK today, what the late-breaking after-hours news could mean, and what to keep on your radar before U.S. markets open Thursday, Dec. 18. Merck stock recap: where MRK stands after the bell (Dec. 17) Merck shares closed at $99.18 on Dec. 17, up 0.93% on
18 December 2025
Merck (MRK) Stock News Today: Why Shares Slid on Dec. 16, 2025 as Analysts Reassess Keytruda, Winrevair, and Merck’s Post‑Patent Strategy

Merck (MRK) Stock News Today: Why Shares Slid on Dec. 16, 2025 as Analysts Reassess Keytruda, Winrevair, and Merck’s Post‑Patent Strategy

Merck & Co., Inc. (NYSE: MRK) stock was among the biggest drags on the Dow Jones Industrial Average in Tuesday’s session (December 16, 2025), with shares trading lower as investors weighed broad market pressure alongside a fast-moving set of company-specific catalysts—ranging from regulatory momentum for Winrevair to ongoing efforts to protect Keytruda ahead of looming patent headwinds. MarketWatch+1 As of the latest trade at 16:41 UTC, Merck shares were $98.05, down 2.21% on the day, after trading between $96.85 and $100.49. Merck stock price action on Dec. 16: a Dow-weighted drop with no single headline Merck’s decline mattered more than
16 December 2025
Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

December 15, 2025 — Merck & Co., Inc. (NYSE: MRK) traded around $99.59 in Monday afternoon action, down about 0.23% on the day, as investors balanced a fresh wave of bullish analyst updates against a busy set of catalysts spanning Winrevair, Keytruda, vaccines, and headline regulatory scrutiny. The setup for MRK stock into year-end is increasingly about “what comes after Keytruda,” and the story is getting more layered: an expanded European pathway for Winrevair (sotatercept), a higher dividend heading into the ex-dividend date, and new legal and policy crosswinds around Merck’s newer product rollouts and the U.S. vaccine environment. What’s
15 December 2025
··
Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck & Co., Inc. (NYSE: MRK) heads into Monday’s U.S. session (December 15, 2025) with investors juggling a mix of near-term headlines and long-term franchise questions: a fresh dividend “reset” that makes Dec. 15 an important calendar day, ongoing scrutiny around RSV prevention products, and high-stakes execution on the company’s plan to diversify beyond Keytruda ahead of the drug’s expected loss of exclusivity later this decade. MarketWatch+2Reuters+2 Below is what to know before the opening bell. MRK stock: where shares stand heading into Monday Merck shares most recently closed at $100.30 on Friday, Dec. 12, extending a three-day winning streak
14 December 2025
·
Merck (MRK) Stock Update: This Week’s News, Key Catalysts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Merck (MRK) Stock Update: This Week’s News, Key Catalysts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) ended Friday, December 12, 2025, at $100.30, climbing 1.30% on the day and finishing slightly higher for the week after a choppy stretch driven by vaccine-policy headlines and scrutiny around RSV preventive therapies. StockAnalysis Below is a detailed, Google News/Discover–ready look at what moved Merck stock this week, what the latest company and sector headlines mean for MRK, what analysts are forecasting, and what investors are watching in the week ahead. Merck stock performance this week: A late rebound after early pressure Closing price (Dec. 12): $100.30.MRK’s weekly story was less about a single
13 December 2025
··
Merck (MRK) Stock After Hours on Dec. 12, 2025: Winrevair EU Tailwind, Analyst Targets, and What to Watch Before the Next Open

Merck (MRK) Stock After Hours on Dec. 12, 2025: Winrevair EU Tailwind, Analyst Targets, and What to Watch Before the Next Open

Merck & Company, Inc. (NYSE: MRK) ended Friday, December 12, 2025, as a relative bright spot in a broadly weak session for U.S. equities. The stock closed at $100.30 (+1.30%), extending its winning streak to three straight days even as the S&P 500 fell 1.07%. MarketWatch After the bell, trading was muted: one widely followed quote feed showed MRK at about $100.28 in after-market trading (around 7:04 p.m. ET)—essentially flat versus the close, suggesting investors had largely priced in the day’s catalysts by the end of regular hours. Zacks A crucial calendar note: December 13, 2025 is a Saturday, and
13 December 2025
·
Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) stock traded higher on Friday, December 12, 2025, as investors weighed a new European regulatory tailwind for pulmonary arterial hypertension drug WINREVAIR (sotatercept) against a backdrop of policy-driven vaccine headlines, Keytruda-related legal friction in Europe, and a steady stream of Wall Street price-target updates. As of 17:07 UTC (midday New York trading), MRK shares were at $99.69, up $0.68 (+0.69%) on the session. Merck stock price: where MRK stands on Dec. 12, 2025 MRK enters the final stretch of 2025 after a solid two-day run earlier in the week. On Thursday, Dec. 11, Merck
12 December 2025
···
Merck (MRK) Stock News, Forecasts & Analyst Outlook — What Investors Are Watching on December 12, 2025

Merck (MRK) Stock News, Forecasts & Analyst Outlook — What Investors Are Watching on December 12, 2025

Merck & Co., Inc. (NYSE: MRK) heads into mid‑December with its stock back near the psychologically important $100 level—and with the kind of headline mix that makes long-term pharma investing feel like chess played on a trampoline: upbeat analyst upgrades and pipeline optimism on one side, and fresh regulatory scrutiny plus the ever-present “Keytruda patent cliff” narrative on the other. As of the latest close, Merck shares finished at about $99.01 after a positive session, though they lagged some large-cap pharma peers on the day. MarketWatch Below is a detailed, publication-ready roundup of the most current MRK stock news, forecasts,
12 December 2025
·
Merck (MRK) Stock After Hours on December 10, 2025: What to Watch Before the December 11 Open

Merck (MRK) Stock After Hours on December 10, 2025: What to Watch Before the December 11 Open

Merck & Co., Inc. (NYSE: MRK) heads into the December 11, 2025 U.S. trading session with its share price stabilizing after a volatile stretch driven by earnings, pipeline news, and a major flu-drug acquisition. Here’s a structured look at what happened after the bell on December 10 – and what investors should know before the market opens on December 11. How Merck Stock Traded on December 10, 2025 Merck shares rebounded modestly during the regular session on Wednesday, December 10. Multiple real-time feeds show the stock closing around $97.62, up roughly 0.7–0.8% on the day, after a sharp decline earlier
11 December 2025
·
Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck Stock (MRK) Today – Keytruda Developments, Analyst Price Targets and 2025–2026 Forecast

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight as Wall Street raises price targets, new clinical data hit the tape, and a wave of product approvals and partnerships reshapes the outlook for its blockbuster cancer franchise Keytruda and the broader pipeline. As of late trading on December 10, 2025, Merck stock changes hands around $97.27, up slightly on the day after yesterday’s pullback. MarketWatch+1 Over roughly the past month, shares have climbed about 20%, helped by positive trial results and optimism around newer products like Winrevair. Finviz This article walks through the latest news from December 10,
10 December 2025
···
Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Note: This article is for informational purposes only and does not constitute investment advice. Merck stock recap: What happened on December 9, 2025? Merck & Co., Inc. (NYSE: MRK) closed Tuesday, December 9, 2025 at $96.89, down 2.06% on the day, after trading between an intraday low of $96.06 and a high of $99.85. Volume was elevated at about 15.3 million shares, above recent averages, signaling active institutional and trader participation.StockAnalysis In after-hours trading, Merck ticked slightly higher to $96.91 around 7:04 p.m. ET, essentially flat versus the close and suggesting no major new company‑specific headline hit the tape after
10 December 2025
··
Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight. As of the afternoon of December 8, 2025, Merck shares trade around $98–99, down about 1% on the day and modestly below their recent 52‑week high of $105.84 reached in late November. That pullback comes after a powerful rebound from a May low near $76, driven by excitement over new cardiovascular and respiratory drugs, plus a $9.2 billion flu‑drug acquisition — even as investors remain focused on the looming 2028 patent cliff for Keytruda and fresh regulatory headwinds.Finviz+2Reuters+2 Below is a detailed, news‑ready rundown of today’s key headlines, stock
8 December 2025
··
Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Updated: December 7, 2025 Merck & Co., Inc. (NYSE: MRK) — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt offering, secured fresh regulatory wins in its cardiopulmonary and animal-health franchises, boosted its dividend, and simultaneously ran into a new patent roadblock for its subcutaneous Keytruda injection in Germany. PR Newswire+4Wikipedia+4Stock Titan+4 Against that backdrop, MRK stock is trading near the top of its 52‑week range, and Wall Street is sharpening its forecasts for 2026 and beyond. MRK stock price
7 December 2025
···
Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

As of the close on December 4, 2025, Merck & Co., Inc. (NYSE: MRK) shares finished at $100.86, down about 1.4% on the day, with after‑hours trading essentially flat around $100.83. The stock sits near the upper end of its 52‑week range of $73.31–$105.84, with a market value of roughly $250 billion, a trailing P/E around 13.3 and a forward P/E just under 12.MarketBeat+3StockAnalysis+3StockAnalysis+3 That defensive valuation, combined with a freshly raised dividend and a packed news pipeline, is keeping MRK firmly on the radar of income investors and growth‑oriented healthcare buyers alike. Below is a detailed, news‑ready rundown of
4 December 2025
··
Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

On Friday, 28 November 2025, Merck & Co., Inc. (NYSE: MRK) continued to trade near its 52‑week highs as a wave of fresh institutional filings, bullish research notes, and recent oncology approvals kept the spotlight firmly on the pharmaceutical giant. The stock closed around $104.5 per share, after trading between roughly $104 and $105 on the day, leaving Merck’s market capitalization near $260 billion.Yahoo Finance+1 While the share price is up only about 2–3% over the past year, nearly all of that gain has arrived in the last month: one recent analysis notes a 20.8% jump over the past 30
28 November 2025
···
Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck & Co., Inc. (NYSE: MRK) is back in the market’s spotlight this Tuesday, with the pharmaceutical giant’s shares extending a powerful rally fuelled by fresh regulatory wins and a major Wall Street upgrade. As of early-afternoon trading on 25 November 2025, Merck stock is changing hands around $104–$105, up roughly 4% on the day and trading just below its 52‑week high near $105.07.Zacks+1 The move makes Merck one of the biggest blue-chip gainers, helping drive the Dow Jones Industrial Average higher by more than 400 points and contributing meaningfully to gains in the S&P 500 as well.MarketWatch+1 Behind today’s
25 November 2025
··
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Cidara Therapeutics, Inc. (NASDAQ: CDTX) is at the center of Wall Street’s attention today after Merck & Co., Inc. (NYSE: MRK) agreed to acquire the San Diego–based biotech in a cash deal valued at approximately $9.2 billion, sending CDTX shares more than 100% higher in a single session. Reuters+1 Below is a detailed look at today’s news (14 November 2025), the science behind Cidara’s lead flu-prevention asset CD388, the stock market reaction, and the wave of shareholder-law-firm investigations that emerged within hours of the announcement. Merck to Acquire Cidara for $221.50 Per Share in Cash Merck and Cidara announced this
14 November 2025
··
1 … 3 4 5

Stock Market Today

Applied Materials stock jumps 6% into a packed week — what matters before Monday

7 February 2026
New York, February 7, 2026, 15:51 (EST) — Market closed. Applied Materials (AMAT) shares rose 6.1% on Friday to close at $322.51, extending a two-day rebound as U.S. equities snapped back from a tech-led slide. The stock finished the week about 6% below its 52-week high and traded heavier than its 50-day average. (MarketWatch) With U.S. markets shut for the weekend, the move leaves traders staring at the next catalyst rather than the last tick. Applied sits in the middle of the chipmaking supply chain, and its comments can reset expectations for equipment demand in a hurry. Friday’s bid came
RTX stock faces Pentagon payout curb list next week as dividend stays in play

RTX stock faces Pentagon payout curb list next week as dividend stays in play

7 February 2026
RTX closed at $198.66 Friday, up 1.4%, after declaring a 68-cent quarterly dividend payable March 19. The Pentagon is expected to name defense contractors early next week that could face limits on dividends and buybacks under a Trump order. RTX’s Raytheon unit has been singled out as “least responsive.” Companies named would have 15 days to submit remediation plans.
Go toTop